The Mycoplasma Testing Market is expected to grow steadily through 2035 as biopharmaceutical companies increase investment in quality-control systems. The need to detect contamination in cell cultures and biological manufacturing processes makes testing an essential laboratory function.

MRFR estimates that the market will grow from USD 1.21 billion in 2025 to USD 3.52 billion by 2035, representing a CAGR of 10.20%.

The growth of biologics is one of the strongest factors shaping the forecast. Modern pharmaceutical pipelines increasingly include antibodies, recombinant proteins, vaccines, and cell-based products. These products depend on carefully controlled biological manufacturing environments.

Cell and gene therapy represents another important future opportunity. As more therapies move toward commercial manufacturing, testing requirements are expected to increase across cell banks, raw materials, manufacturing processes, and final products.

The industry is also moving toward rapid testing. Traditional culture approaches remain important in certain workflows, but molecular assays can provide faster results and support shorter manufacturing decision cycles.

Digital PCR may gain market share because of its sensitivity and quantitative capabilities. Automated platforms may also become more common as laboratories seek to reduce manual work.

Contract testing is likely to expand as biotechnology companies seek specialized services. Outsourcing allows smaller organizations to access validated testing capabilities without establishing complete internal laboratories.

Regional growth will vary. North America benefits from established biopharmaceutical manufacturing and regulatory infrastructure, while Asia-Pacific offers strong expansion potential because of increasing pharmaceutical production and laboratory investment.

Future market development will depend on regulatory standards, technology adoption, biomanufacturing investment, and the increasing complexity of biological therapies.

Frequently Asked Questions

What CAGR is expected through 2035?
MRFR projects a CAGR of approximately 10.20% for 2026–2035.

Why is quality control important?
Effective contamination testing supports the integrity and consistency of biological research and manufacturing.

What technology may grow rapidly?
Digital PCR and automated molecular testing platforms are expected to offer significant opportunities.